To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.
• Age ≥ 18 years old.
Diagnosed with intracranial hemorrhage confirmed by CT scan.
Managed conservatively regarding clinical guidelines.
Able to provide informed consent or have a legal representative provide consent.
• Patients with a history of previous brain surgery or significant neurological disorders.
Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease).
Allergy or contraindication to febuxostat.
Pregnant or breastfeeding women.